Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Solomon

Showing results (1491-1500 of 1,873) with videos related to

Pageof 188
Sort By:
JACC. Heart Failure|December 9, 2023
Standardized Definitions for Evaluation of Acute Decompensated Heart Failure Therapies: HF-ARC Expert Panel PaperAnuradha Lala, Carine E Hamo, Biykem Bozkurt, et al.
JAMA Cardiology|October 3, 2022
Time to Clinical Benefit of Dapagliflozin in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Prespecified Secondary Analysis of the DELIVER Randomized Clinical TrialMuthiah Vaduganathan, Brian L Claggett, Pardeep Jhund, et al.
JAMA|October 11, 2024
Electronic Nudges to Increase Influenza Vaccination in Patients With Chronic Diseases: A Randomized Clinical TrialNiklas Dyrby Johansen, Muthiah Vaduganathan, Ankeet S Bhatt, et al.
Journal of the American College of Cardiology|May 24, 2023
Right Ventricular Function and Pulmonary Coupling in Patients With Heart Failure and Preserved Ejection FractionRiccardo M Inciardi, Martin Abanda, Amil M Shah, et al.
Circulation. Heart Failure|April 18, 2018
Racial Differences in Characteristics and Outcomes of Patients With Heart Failure and Preserved Ejection Fraction in the Treatment of Preserved Cardiac Function Heart Failure TrialEldrin F Lewis, Brian Claggett, Amil M Shah, et al.
JAMA Cardiology|March 28, 2026
EMPEROR-Preserved Risk Model and Outcomes in the FINEARTS-HF Trial: A Prespecified Secondary Analysis of FINEARTS-HFMisato Chimura, Kirsty McDowell, Pardeep S Jhund, et al.
JAMA Cardiology|June 4, 2025
Cellular Adhesion Molecules and Adverse Outcomes in Chronic Heart Failure: Findings From the DAPA-HF Randomized Clinical TrialKirsty McDowell, Paul Welsh, Kieran F Docherty, et al.
JACC. Heart Failure|April 28, 2022
Relationship of Dapagliflozin With Serum Sodium: Findings From the DAPA-HF TrialSu Ern Yeoh, Kieran F Docherty, Pardeep S Jhund, et al.
JACC. Heart Failure|July 28, 2022
Effects of Dapagliflozin According to the Heart Failure Collaboratory Medical Therapy Score: Insights From DAPA-HFJawad H Butt, Pooja Dewan, Ersilia M DeFilippis, et al.
JACC. Heart Failure|April 10, 2025
Finerenone Across the Spectrum of Kidney Risk in Heart Failure: The FINEARTS-HF TrialJohn W Ostrominski, Finnian R Mc Causland, Brian L Claggett, et al.
Pageof 188

Showing results (1491-1500 of 1,873) with videos related to

Sort By:
Pageof 188
JACC. Heart Failure|December 9, 2023
Standardized Definitions for Evaluation of Acute Decompensated Heart Failure Therapies: HF-ARC Expert Panel PaperAnuradha Lala, Carine E Hamo, Biykem Bozkurt, et al.
JAMA Cardiology|October 3, 2022
Time to Clinical Benefit of Dapagliflozin in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Prespecified Secondary Analysis of the DELIVER Randomized Clinical TrialMuthiah Vaduganathan, Brian L Claggett, Pardeep Jhund, et al.
JAMA|October 11, 2024
Electronic Nudges to Increase Influenza Vaccination in Patients With Chronic Diseases: A Randomized Clinical TrialNiklas Dyrby Johansen, Muthiah Vaduganathan, Ankeet S Bhatt, et al.
Journal of the American College of Cardiology|May 24, 2023
Right Ventricular Function and Pulmonary Coupling in Patients With Heart Failure and Preserved Ejection FractionRiccardo M Inciardi, Martin Abanda, Amil M Shah, et al.
Circulation. Heart Failure|April 18, 2018
Racial Differences in Characteristics and Outcomes of Patients With Heart Failure and Preserved Ejection Fraction in the Treatment of Preserved Cardiac Function Heart Failure TrialEldrin F Lewis, Brian Claggett, Amil M Shah, et al.
JAMA Cardiology|March 28, 2026
EMPEROR-Preserved Risk Model and Outcomes in the FINEARTS-HF Trial: A Prespecified Secondary Analysis of FINEARTS-HFMisato Chimura, Kirsty McDowell, Pardeep S Jhund, et al.
JAMA Cardiology|June 4, 2025
Cellular Adhesion Molecules and Adverse Outcomes in Chronic Heart Failure: Findings From the DAPA-HF Randomized Clinical TrialKirsty McDowell, Paul Welsh, Kieran F Docherty, et al.
JACC. Heart Failure|April 28, 2022
Relationship of Dapagliflozin With Serum Sodium: Findings From the DAPA-HF TrialSu Ern Yeoh, Kieran F Docherty, Pardeep S Jhund, et al.
JACC. Heart Failure|July 28, 2022
Effects of Dapagliflozin According to the Heart Failure Collaboratory Medical Therapy Score: Insights From DAPA-HFJawad H Butt, Pooja Dewan, Ersilia M DeFilippis, et al.
JACC. Heart Failure|April 10, 2025
Finerenone Across the Spectrum of Kidney Risk in Heart Failure: The FINEARTS-HF TrialJohn W Ostrominski, Finnian R Mc Causland, Brian L Claggett, et al.
Pageof 188